| Yang, Haiyan |
NCT06285370: A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy |
|
|
| Recruiting | 4 | 20 | RoW | Mogamulizumab | Kyowa Kirin China Pharmaceutical Co., Ltd. | Cutaneous T-Cell Lymphoma | 10/25 | 01/26 | | |
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 250 | Europe, Canada, Japan, US, RoW | LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 08/23 | 05/27 | | |
NCT05051891: A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma |
|
|
| Recruiting | 3 | 356 | RoW | Orelabrutinib and R-CHOP, R-CHOP | Beijing InnoCare Pharma Tech Co., Ltd. | Treatment-naїve Mantle Cell Lymphoma | 12/24 | 12/27 | | |
| Active, not recruiting | 3 | 500 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa | Loxo Oncology, Inc., Eli Lilly and Company | Lymphoma, Mantle-Cell | 12/25 | 07/26 | | |
| Recruiting | 2 | 26 | RoW | Rituximab, chidamide, lenalidomde | Zhejiang Cancer Hospital | Angioimmunoblastic T-cell Lymphoma, Chemotherapy Effect, Chemotherapeutic Toxicity | 03/22 | 12/22 | | |
NCT06511895: AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27) |
|
|
| Recruiting | 2 | 150 | RoW | AZD4205 | Dizal Pharmaceuticals | Peripheral T Cell Lymphoma | 05/25 | 12/26 | | |
NCT03934567: A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma |
|
|
| Recruiting | 2 | 96 | RoW | Abexinostat | Xynomic Pharmaceuticals, Inc. | Lymphoma, Follicular | 02/24 | 09/24 | | |
| Active, not recruiting | 2 | 59 | RoW | CD19-targeted Chimeric Antigen Receptor (CAR) T Cells | Shanghai Ming Ju Biotechnology Co., Ltd. | Mantle Cell Lymphoma | 10/23 | 08/28 | | |
O-Gemox, NCT05381506: Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma |
|
|
| Not yet recruiting | 2 | 77 | RoW | Orelabrutinib and Gemox, O-Gemox | Sun Yat-sen University | DLBCL | 12/23 | 12/25 | | |
NCT05716087: A Study of Rocbrutinib in Participants with Relapse or Refractory Mantle Cell Lymphoma |
|
|
| Active, not recruiting | 2 | 62 | RoW | Rocbrutinib, NWP-775, LP-168 | Guangzhou Lupeng Pharmaceutical Company LTD. | Mantle Cell Lymphoma (MCL) | 12/24 | 12/25 | | |
NCT04849351: Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma |
|
|
| Recruiting | 2 | 185 | RoW | HMPL-689, Phosphatidylinositol 3-kinase-δ inhibitor | Hutchison Medipharma Limited | Marginal Zone Lymphoma, Follicular Lymphoma | 04/24 | 12/24 | | |
NCT03936153: Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) |
|
|
| Recruiting | 2 | 170 | RoW | abexinostat | Xynomic Pharmaceuticals, Inc. | Diffuse Large B-cell Lymphoma (DLBCL) | 12/24 | 05/25 | | |
NCT05290090: ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL |
|
|
| Recruiting | 2 | 31 | RoW | Rituximab, Lenalidomide, Zanubrutinib and RCHOP, BGB-3111 | Zhejiang Cancer Hospital | Diffuse Large B Cell Lymphoma | 06/24 | 12/25 | | |
NCT06674096: RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL |
|
|
| Recruiting | 2 | 44 | RoW | RLC-CRCHOP | Zhejiang Cancer Hospital | Double-expressor Lymphoma | 12/29 | 06/30 | | |
NCT05992597: ZR2 Sequential Immunochemotherapy for Newly Treated MCL |
|
|
| Recruiting | 2 | 48 | RoW | ZR2 RDHAP | Zhejiang Cancer Hospital | Rituximab, Lenalidomide, Zebutinib ，Mantle Cell Lymphoma | 08/25 | 12/26 | | |
NCT06086197: A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL |
|
|
| Recruiting | 2 | 41 | RoW | Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin | Zhejiang Cancer Hospital | Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory | 10/25 | 10/26 | | |
NCT04390737: Evaluate the Safety and Clinical Activity of HH2853 |
|
|
| Recruiting | 1/2 | 254 | US, RoW | HH2853 Tablets | Haihe Biopharma Co., Ltd. | FL Lymphoma, Epithelioid Sarcoma, Peripheral T Cell Lymphoma, Advanced Solid Tumor | 12/25 | 12/25 | | |
NCT05155839: Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL) |
|
|
| Recruiting | 1 | 108 | RoW | MRG001 | Shanghai Miracogen Inc. | Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL) | 10/22 | 10/23 | | |
